Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia
Crossref DOI link: https://doi.org/10.1038/leu.2015.318
Published Online: 2015-11-19
Published Print: 2016-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Zabriskie, M S
Eide, C A
Yan, D
Vellore, N A
Pomicter, A D
Savage, S L
Druker, B J
Deininger, M W
O'Hare, T
Text and Data Mining valid from 2015-11-19
Article History
First Online: 19 November 2015
Competing interests
: The authors declare no conflict of interest.